Preview | Collaboration Agreement |

Document Preview

Collaboration Agreement

Click "Add to Cart" button to purchase document.
Documents are emailed immediately after purchase.
You can also browse documents by title, category, or company... or click here for help finding documents.

Title:

Collaboration Agreement

Entities:

Sequenom, Inc.

Date:

2004

Size:

76KB total

Price:

$46

ID:

#325820

► Licensing ► Collaboration Agreements
► Biotech & Drugs ► Commercial Physical & Biological Research

Start of Preview

***CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

COLLABORATION AGREEMENT

BETWEEN

SEQUENOM, INC.

AND

PROCTER & GAMBLE PHARMACEUTICALS, INC.

DECEMBER 17, 2003

TABLE OF CONTENTS

(CONTINUED)


			PAGE
1.	Definitions		1

	1.1	Actions	1

	1.2	Active	1

	1.3	Active Compound	1

	1.4	Affiliate	2

	1.5	Claim	2

	1.6	Controlled	2

	1.7	Diagnostic	2

	1.8	Excluded Field	2

	1.9	FDA	2

	1.0	Field	2

	1.1	First Commercial Sale	2

	1.12	Gene Target	2

	1.13	Information	2

	1.14	Initial Research Team	2

	1.15	Invention	2

	1.16	IND	2

	1.17	Joint Inventions	3

	1.18	Joint Patents	3

	1.19	Licensed Product	3

	1.20	NDA	3

	1.21	Net Sales	3

	1.22	OA	3

	1.23	OP	3

	1.24	Option	3

	1.25	P&G Indemnitees	3

	1.26	P&G Invention	3

	1.27	P&G Know-How	3


		-i-

TABLE OF CONTENTS

(CONTINUED)


			PAGE
	1.28	P&G Patents	3

	1.29	P&G Technology	4

	1.30	Patents	4

	1.31	Phase II	4

	1.32	Phase III	4

	1.33	RC	4

	1.34	Regulatory Agency	4

	1.35	Regulatory Approval	4

	1.36	Research Plan	4

	1.37	Research Program	4

	1.38	Research Term	4

	1.39	Selected Target	4

	1.40	Selected Target Family	4

	1.41	Sequenom Indemnitees	5

	1.42	Sequenom Invention	5

	1.43	Sequenom Know-How	5

	1.44	Sequenom Patents	5

	1.45	Sequenom Technology	5

	1.46	Term	5

	1.47	Therapeutic License	5

	1.48	Third Party	5

	1.49	US	5

2.	CONDUCT OF RESEARCH PROGRAM		5

	2.1	Conduct of Research Program	5

	2.2	Disclosure of Information Regarding Selected Targets to P&G	5

	2.3	Designation of Selected Targets	6

	2.4	Research Program Responsibilities	7

	2.5	Technology Transfer	7


		-ii-

TABLE OF CONTENTS

(CONTINUED)


			PAGE
	2.6	Research Program Expenses	7

3.	GOVERNANCE		7

	3.1	Research Committee	7

	3.2	Research Committee Functions and Powers	8

	3.3	Information and Reports	8

4.	LICENSES		8

	4.1	Option to License Selected Targets	8

	4.2	License Grants for Research Program	8

	4.3	License Grants to P&G for Development and Commercialization	8

	4.4	Rights Granted to Sequenom	9

	4.5	Sublicensing Rights	9

	4.6	No Implied Licenses	9

5.	DEVELOPMENT AND COMMERCIALIZATION; DEVELOPMENT REPORTS		9

	5.1	Development and Commercialization	9

	5.2	Development Reports	9

6.	FEES AND PAYMENTS		10

	6.1	License Fees	10

	6.2	Milestone Payments	10

	6.3	Royalties Payable by P&G	11

	6.4	Sublicense Fees	11

	6.5	Royalty Term	11

7.	PAYMENT; RECORDS; AUDITS		11

	7.1	Payment; Reports	11

	7.2	Exchange Rate; Manner and Place of Payment	12

	7.3	Late Payments	12

	7.4	Withholding of Taxes	12

	7.5	Records and Audits	12


		-iii-

TABLE OF CONTENTS

(CONTINUED)


			PAGE
	7.6	Prohibited Payments	13

8.	INVENTIONS AND INTELLECTUAL PROPERTY		13

	8.1	Inventions	13

	8.2	Patent Prosecution	13

	8.3	Cooperation of the Parties	13

End of Preview

Home Intelligence Services Subscriptions News About Us